St. Jude's renal denervation system nets EU thumbs up

St. Jude Medical has been granted CE Mark approval of its EnligHTN renal denervation system.

Renal denervation is an ablation procedure that seeks to reduce blood pressure in patients with hypertension that is resistant to medical therapy. Clinical data from the EnligHTN I trial about the safety and efficacy of this renal denervation technology will be presented on May 16 at EuroPCR in Paris.

Using the EnligHTN system, an ablation catheter delivers radiofrequency energy to create lesions along the renal sympathetic nerves. The system uses multi-electrode ablation technology. With the basket design, the placement of the ablation catheter allows a pattern of four ablations in 90-second intervals. 

St. Jude is based in St. Paul, Minn.

 

 

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.